De Novo device
BT-001
Better Therapeutics · Diabetes Digital Therapeutic Device (QXC, Class II) · First FDA decision Jul 7, 2023, newest Jul 7, 2023Diabetes
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
De Novo pathway
Device trials
3
Naming "BT-001"
MAUDE reports
0
Brand "BT-001", since 2015
PubMed studies
7
Mentioning "BT-001"
AI summary across all sources
Written by Claude (Anthropic's AI) from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- BT-001New device typeDe Novo
DEN220058 · Decided Jul 7, 2023 · 289 days after receipt
Device type: Diabetes Digital Therapeutic Device (QXC) · Hospital Medicine & Nursing
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Therapeutic Shoes for Persons with DiabetesLocal determinationIn effectL33369CGS Administrators, LLCUpdated Feb 28, 2020
Clinical trials
Device studies on ClinicalTrials.gov that name "BT-001", any status and sponsor, newest update first.
- A Cognitive Behavioral Digital Therapeutic InterventiON for Glycemic Control in Type 2 Diabetes MellitusPivotal-lookingStatus unknown
Better TherapeuticsNot on our public-company list
NCT05302050 · 500 participants · Start Mar 7, 2022 · Primary completion Dec 1, 2025
Device: BT-001; Control Mobile Application · For: Diabetes Type 2
Sites: Boston, Massachusetts
- Pivotal Trial of a Digital Therapeutic for the Treatment of Type 2 DiabetesPivotal-lookingCompleted
Better TherapeuticsNot on our public-company list
NCT04886388 · 668 participants · Start Apr 22, 2021 · Primary completion Mar 9, 2022
Device: BT-001 · For: Type 2 Diabetes
Sites: San Francisco, California; Miami, Florida; Atlanta, Georgia · 6 sites in all
Better TherapeuticsNot on our public-company list
NCT05094401 · 76 participants · Start Oct 4, 2021 · Primary completion Apr 1, 2023
Device: BT-001 · For: Type2 Diabetes
Sites: Plano, Texas
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "BT-001", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code QXC
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "BT-001"[tiab]. The summary above synthesizes these.
- In type 2 diabetes, the BT-001 smartphone app reduced HbA1c more than a control app at 90 d.
Greenblatt LH · Ann Intern Med · 2023Comment
- Cost-Effectiveness Analysis of a Prescription Digital Therapeutic in Type 2 Diabetes.
Davison NJ, Guthrie NL, Medland S, et al. · Adv Ther · 2024Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject 'cold' tumors.
Semmrich M, Marchand JB, Fend L, et al. · J Immunother Cancer · 2022Research Support, Non-U.S. Gov't
- Randomized, Controlled Trial of a Digital Behavioral Therapeutic Application to Improve Glycemic Control in Adults With Type 2 Diabetes.
Hsia J, Guthrie NL, Lupinacci P, et al. · Diabetes Care · 2022Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Cognitive behavioral therapy delivered via digital mobile application for the treatment of type 2 diabetes: Rationale, design, and baseline characteristics of a randomized, controlled trial.
Canonico ME, Hsia J, Guthrie NL, et al. · Clin Cardiol · 2022Clinical Trial Protocol
- Digital Therapeutic Based Randomized Investigation to Improve Glycemic Control in Patients With Type 2 Diabetes and Residual Hyperglycemia on Stable Medical Therapy: Rationale, Design, and Baseline Characteristics of the BRIGHT Trial.
Canonico ME, Hsia J, Masoudi FA, et al. · J Am Heart Assoc · 2025Clinical Trial Protocol, Research Support, Non-U.S. Gov't
- Digital Cognitive Behavioral Therapy Reduces Intensification of Antihyperglycemic Therapy in Patients With Type 2 Diabetes.
Hsia J, Guthrie NL, Berman MA, et al. · AACE Endocrinol Diabetes · 2026
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.